 Home > Active Ingredient News > Blood System > JCO: Final analysis results of Ixazomi combined with lenalidomide + dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM): Phase III clinical study TOURMALINE-MM1

JCO: Final analysis results of Ixazomi combined with lenalidomide + dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM): Phase III clinical study TOURMALINE-MM1

 Last Update: 2021-06-21
 Source: Internet
 Author: User

Tags

high throughput sequencing

bcl 2 inhibitor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The TOURMALINE-MM1 study is a global multicenter, double-blind, placebo-controlled randomized phase III study that evaluates Ixazomib combined with lenalidomide + dexamethasone (Ixazomib-Rd) versus placebo combined with lenalidomide + dexamethasone (Placebo-Rd) Efficacy and safety in relapsed or refractory (RR) multiple myeloma (MM)

There were 360 patients in the Ixazomib-Rd group and 362 patients in the placebo-Rd group

In subgroup analysis, it was found that Ixazomib-Rd has a tendency to benefit in some subgroups, such as refractory after any line treatment (HR=0.

OS for two groups and subgroups analysis

For the following patients , Ixazomib-Rd treatment has achieved a numerical benefit of OS, patients with del(17p) (HR=0.

OS with different genetic risks

In the two groups, 259 patients (71.

The median OS of the two groups who received the posterior protease inhibitor was 52.

OS in the two groups that received or did not receive late-line protease inhibitors

During the 7-year follow-up period, no new or additional safety incidents occurred

Adverse events

In summary, the progression-free survival (PFS) benefit of Ixazomib-Rd in the treatment of relapsed or refractory multiple myeloma (RRMM) does not translate into the benefit of OS
.
However, in some subgroups, the Ixazomib-Rd group has a tendency to benefit from OS
.
The progression-free survival (PFS) benefit of Ixazomib-Rd in the treatment of relapsed or refractory multiple myeloma (RRMM) did not translate into the benefit of OS
.
However, in some subgroups, the Ixazomib-Rd group has a tendency to benefit from OS
.
The progression-free survival (PFS) benefit of Ixazomib-Rd in the treatment of relapsed or refractory multiple myeloma (RRMM) did not translate into the benefit of OS
.
However, in some subgroups, the Ixazomib-Rd group has a tendency to benefit from OS
.

Original source:

Paul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
J Clin Oncol.
2021 Jun 11; JCO2100972.
doi: 10.
1200/JCO.
21.
00972.
Online ahead of print.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.